AbbVie Presents New Data on Efficacy of Upadacitinib in Moderate ...

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ ...

24, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEL, a Phase 3 induction study, showing ...

With study success, AbbVie's arthritis hopeful looks to be a safer bet

AbbVie Inc.'s experimental arthritis drug upadacitinib succeeded in its fourth and largest-to-date Phase 3 study, beating out both placebo ...

AbbVie Presents New Data at the European E-Congress of ...

It is the sixth study in the SELECT rheumatoid arthritis clinical trial program, evaluating efficacy and safety of RINVOQ compared to abatacept ...

AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ) in ...

AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid ...

100 - AbbVie News Center

All news · September 25, 2024. New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and ...

AbbVie shares positive results for Rinvoq in head-to-head atopic ...

AbbVie has announced positive topline results from a head-to-head study of its selective JAK inhibitor, Rinvoq (upadacitinib), in adults and adolescents with ...

AbbVie to Present New Analyses from Pivotal Phase 3 Studies for ...

"I'm encouraged to see results showing a high proportion of patients treated with upadacitinib achieved EASI 90, or almost clear skin, and ...

AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 ...

* "These data suggest the potential of upadacitinib to help counter inflammation, relieve pain and improve function, helping patients living ...

AbbVie Presents New Late-Breaking Phase 2b Data on ...

In an exploratory analysis, results at week 2 of treatment with upadacitinib showed all dose groups (30/15/7.5 mg once-daily) achieved ...

AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical ...

The SLEek study met the primary endpoint of SLE Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once ...

AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets ...

RINVOQ, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is approved for the treatment of moderate to severe active ...

New Long-term Data from RINVOQ™ (upadacitinib, 15 mg) Phase 3 ...

Additionally, approximate two-year data (96 weeks) from the SELECT-EARLY (upadacitinib, 15 mg and 30 mg) and SELECT-COMPARE clinical trials ...

AbbVie News Center - News

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®. April 25, 2024. New Data Show RINVOQ® (upadacitinib) ...

AbbVie hits all endpoints for rheumatoid arthritis test - Fierce Biotech

AbbVie says its investigational rheumatoid arthritis (RA) drug upadacitinib bested placebo in reducing symptoms of the disease, ...

AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient ...

NORTH CHICAGO, Ill., Sept. ... Results from a pre-specified, interim analysis from the Phase 2b dose-ranging study showed that treatment with ...

AbbVie Showcases New Analyses and Real-World Data Across ...

Efficacy and Safety of Risankizumab in Psoriasis Patients Who Had a. Suboptimal Response to Secukinumab or Ixekizumab. Poster Session. P1537.

Abbvie's Upadacitinib Meets Primary And Key Efficacy Endpoints In ...

* ABBVIE INC - SAFETY PROFILE OF UPADACITINIB WAS CONSISTENT WITH PREVIOUSLY REPORTED RESULTS, WITH NO NEW SAFETY SIGNALS DETECTED. * ABBVIE ...

New Long-Term Data from Upadacitinib Phase 3 Studies in ...

"These data continue to support the potential of upadacitinib to help maintain consistent disease control for patients living with moderately to ...

AbbVie Presents Additional Outcomes Data from Three Upadacitinib ...

"Across three Phase 3 studies with different patient populations, patients treated with upadacitinib reported improvements in physical function, ...

November 18, 2024 - AbbVie News Center

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus ... AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety ...